 |
市場調査レポート
商品コード
987864
弱毒生水痘ワクチンの世界市場：2020～2027年Global Varicella Attenuated Live Vaccine Market - 2020-2027 |
||||||
| 弱毒生水痘ワクチンの世界市場：2020～2027年 |
|
出版日: 受注後作成
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: お問合せ
|
カンジダ症の有病率の上昇、研究開発費の増加、および新興市場における未開拓の機会は、市場の成長をけん引する要因となっています。ただし、発展途上経済諸国における外陰膣カンジダ症に関する認識の欠如は、予測期間中の市場成長を妨げると見込まれています。
当レポートでは、世界の弱毒生水痘ワクチン市場について調査分析し、市場の概要、市場成長への影響要因、各セグメント・地域別による市場規模と前年比成長、および主要企業などについて分析しています。
Varicella zoster, also known as Human alphaherpesvirus 3, causes herpes zoster and chicken pox in humans. The infection instigated by this virus can be avoided by the use of vaccinations that are particularly formulated to provide immunity against the virus. These vaccines vary from each other on the basis of their contents. For instance, monovalent varicella vaccine comprises only one strain of virus whereas the combination varicella vaccine includes more than one strain of virus and offers immunity against more than one virus.
The global varicella attenuated live vaccine market size was worth US$ XX billion in 2019 and further predicted to reach US$ XX billion by 2027, at a CAGR of XX% during the forecast period (2020-2027).
Certain factors that are leading the market growth include the increasing prevalence of candidiasis, the increasing R&D expenditure, and untapped opportunities in the emerging markets. However, the lack of awareness regarding the vulvovaginal candidiasis in underdeveloped economies will hamper the market growth during the forecast period.
Expected increase in the prevalence of chicken pox
According to CDC (Centers for Disease Control and Prevention), more than 3.5 million cases of chickenpox, along with 9,000 hospitalizations, and 100 mortalities are averted by chickenpox vaccination in the U.S. This, in turn, contributes to the growth of the varicella attenuated live vaccine market. There are several companies that are strengthening their position by driving national programs for support and coordination among national, local, regional, and international stakeholders, has accomplished in improving immunization coverage rates.
Increasing government focus on varicella attenuated live vaccine
The government support is increasing with the rising focus on driving immunization programs to lessen the disease burden impact that aids in the growth of the varicella attenuated live vaccine market. A few of manufacturers in collaboration with Gavi, WHO, the World Bank, and UNICEF are committed to boost immunization programs and speed up the introduction of new vaccines. This would contribute to the growth of the varicella attenuated live vaccine market.
COVID-19 Impact Analysis
A decrease in the market value of varicella attenuated live vaccine is expected in 2020, backed by the decline in the hospital visits, which in turn, also hampered the functioning of immunization programs. Therefore, the demand for varicella attenuated live vaccine decreased amid the COVID-19 pandemic, which in turn, declined the sales of the vaccine in 2020.
Based on the application, the varicella attenuated live vaccine market has been classified into Chickenpox Immunization, Herpes Zoster Immunization, MMRV Immunization, and econazole.
Chickenpox Immunization segment contributed significant share to the global varicella attenuated live vaccine market in 2019
Chicken pox immunization contributed the largest varicella attenuated live vaccine market share in 2019, owing to immunization employed with an initial aim of developing immunity against chicken pox. It is highly contagious and is typically spread by direct contact or via air by sneezing and coughing. The illness commonly causes an itchy rash and leads to the formation of more than 400 blisters all over the body. Additionally, it causes fussiness, headache, and coughing in the patients.
Based on the product, the varicella attenuated live vaccine market has been classified into monovalent varicella vaccine and combination varicella vaccine.
Monovalent Varicella Vaccine lead the market throughout the forecast period
Monovalent Varicella Vaccine segment led the overall market with a share in 2019. It is also expected to foresee rapid growth during the forecast period, as such vaccines demonstrate lesser chances of causing febrile seizures in children as compared to combination vaccines. In addition, easy availability and presence of wide product portfolio are the other factors that enhance the varicella attenuated vaccine market growth.
Geographical Analysis
Based on geography, the study analyzes the varicella attenuated live vaccine market in the global market, including North America, South America, Europe, Asia-Pacific, and the Middle East & Africa.
North America leads the global market throughout the forecast period
North America dominated the global varicella attenuated live vaccine market with the largest share in terms of value and volume globally, followed by Europe and the Asia Pacific. The US dominated the North American varicella attenuated live vaccine market in 2019. The presence of skilled healthcare professionals and the presence of key market players, such as Merck & Co., Inc., are other factors that are supporting the market growth.
Moreover, Asia Pacific is expected to project the fastest growth rate in the varicella attenuated live vaccine market during the forecast period. China dominates the market, whereas India is estimated to exhibit considerable growth in the Asia Pacific varicella attenuated live vaccine market during the forecast period. The gradual rise in vaccination for varicella and the rapidly evolving life science industry are certain factors augmenting the market growth in the region.
The varicella attenuated live vaccine market is highly competitive, owing to the large presence of varicella attenuated live vaccine brands. The key varicella attenuated live vaccine players include Bio-Med Pvt. Limited, GlaxoSmithKline PLC, GC Pharma (Green Cross Holdings), Novo Medi Sciences Pvt. Ltd., Emcure Pharmaceuticals Limited, Sanofi SA, Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceutical Company Limited. The crucial players are adopting new product launches and expansion strategies for global growth in the varicella attenuated live vaccine market.
Merck & Co. Inc.
Overview: Merck & Co. Inc. is a research-based pharmaceutical company that offer healthcare solutions via its prescription medicines, biologic therapies, vaccines, animal health products. The company sell its products to hospitals, drug wholesalers and retailers, government agencies, and other institutions. It generates over 40.0% of its revenue from the US.
Product Portfolio: The company's portfolio comprises VARIVAX and ZOSTAVAX.
The global varicella attenuated live vaccine market report would provide access to an approx. 51 market data tables, 50 figures, and 260 pages.
LIST NOT EXHAUSTIVE
比較リスト
